StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $14.48 | $14.76 | +1.93% | 1.1M |
| 05-13 | $14.77 | $14.38 | -2.64% | 2.4M |
| 05-14 | $14.54 | $13.28 | -8.67% | 3.4M |
| 05-15 | $12.86 | $12.25 | -4.74% | 3.3M |
| 05-18 | $12.29 | $11.70 | -4.80% | 2.0M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 |
|---|---|---|---|---|
Revenue | $9.89M | $0.00 | $79.89M | $49.88M |
Operating Income | $-17.42M | $-34.97M | $-130.73M | $-90.90M |
Net Income | $56.06M | $-33.46M | $-86.39M | $-28.59M |
EPS (Diluted) | $0.62 | $-0.58 | $-1.39 | $-1.02 |
Total Assets | $286.17M | $235.16M | $123.43M | $145.39M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $1.91M | $4.26M | $7.42M | $12.70M |
Free Cash Flow OCF − CapEx | $-14.51M | $-35.88M | $-91.71M | $-67.95M |
Shares Outstanding | 72.00M | 58.06M | 62.54M | 62.49M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.